A Therapeutic Equivalent to SOMATULINE® DEPOT*

Lanreotide Injection

120 mg/0.5 mL

DETAILS
NDC 69097-906-67
STRENGTH 120 mg/0.5 mL
RLD Somatuline® Depot*
TE Rating AB
SELLING UNIT 1
SELLING UNITS PER SHIPPING CASE 20
STORAGE 2°C to 8°C (36°F to 46°F)
Protect from light
SHELF LIFE 18 months

*Somatuline® Depot is a registered trademark of Ipsen Pharma S.A.S.

A Therapeutic Equivalent to SOMATULINE® DEPOT*

Lanreotide Injection

120 mg/0.5 mL

69097-906-67

120 mg/0.5 mL
Somatuline® Depot *
2°C to 8°C (36°F to 46°F)
Protect from light

18 months

*Somatuline® Depot is a registered trademark of Ipsen Pharma S.A.S.

Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Lanreotide Injection
120 mg/0.5 mL
Product Overview Sheet

Looking for a print-friendly version of Lanreotide Injection information for health care providers?

Download our Product Overview sheet to share with your colleagues. Please click here to contact us if you have any questions about Lanreotide Injection.

Download

Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Lanreotide Injection
120 mg/0.5 mL
Product Overview Sheet

Looking for a print-friendly version of Lanreotide Injection information for health care providers?

Download our Product Overview sheet to share with your colleagues. Please click here to contact us if you have any questions about Lanreotide Injection.

Download

Packaging Information
Dosing & Administration

Before administering Lanreotide Injection 120mg, it’s important for healthcare providers to know what to expect in each box and how to properly inject the medication. This medication should be administered under the supervision of a healthcare professional and must be left at room temperature for 30 minutes before administration.

Each Lanreotide Injection 120 mg/0.5 mL box contains:

  • One prefilled syringe containing 120mg of Lanreotide
  • Instructions for Use Leaflet

Please refer to the Important Safety Information or the accompanying full Prescribing Information which includes additional Important Safety Information as well as the Instructions for Use.

For privacy reasons YouTube needs your permission to be loaded. For more details, please see our Privacy Policy.
I Accept
Packaging Information
Dosing & Administeration

Before administering Lanreotide Injection 120mg, it’s important for healthcare providers to know what to expect in each box and how to properly inject the medication.

This medication should be administered under the supervision of a healthcare professional and must be left at room temperature for 30 minutes before administration.

Each Lanreotide Injection 120 mg/0.5 mL box contains:

  • One prefilled syringe containing Lanreotide 120 mg (provided as Lanreotide acetate)
  • Instructions for Use Leaflet

Please refer to the Important Safety Information or the accompanying full Prescribing Information which includes additional Important Safety Information as well as the Instructions for Use.

For privacy reasons YouTube needs your permission to be loaded. For more details, please see our Privacy Policy.
I Accept

A Reference Guide To
Billing & Coding

LANREOTIDE INJECTION

120 mg/0.5 mL

At Cipla, we are committed to providing helpful reimbursement information for Physician Offices and Facilities to ensure patient access to appropriate medicines.

Get the Guide

A Reference Guide To
Billing & Coding

At Cipla, we are committed to providing helpful reimbursement information for Physician Offices and Facilities to ensure patient access to appropriate medicines.

LANREOTIDE INJECTION

120 mg/0.5 mL

Get The Guide

Interested in ordering directly from Cipla? Please fill out the form below.

WHOLESALER/DISTRIBUTOR ORDER ENTRY NUMBER
CENCORA MCKESSON
10289332 2906519

Interested in ordering directly from Cipla? Please fill out the form below.

10289332

2906519

WANT TO LEARN MORE ABOUT

LANREOTIDE INJECTION

120 mg/0.5 mL

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.

WANT TO LEARN MORE ABOUT

LANREOTIDE INJECTION

120 mg/0.5 mL

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.

Important Safety Information
Please Read Before Administration

Contraindications:

Hypersensitivity to lanreotide.

Warnings and Precautions

Cholelithiasis and Complications of Cholelithiasis: Monitor patients periodically discontinue if complications of cholelithiasis are suspected. Gallstones may occur; consider periodic monitoring.

Hyperglycemia and Hypoglycemia: Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly.

Most Common Adverse Reactions (>10%) include abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, hyperglycemia, hypertension, and cholelithiasis.

Immunogenicity: There is potential for immunogenicity.

Drug Interactions

Insulin and Oral Hypoglycemic Drugs: Blood glucose levels should be monitored and antidiabetic treatment should be adjusted accordingly.

Cyclosporine: Lanreotide Injection may decrease the absorption of cyclosporine. Dosage adjustment of cyclosporine may be needed.

Bromocriptine: Lanreotide may increase the absorption of bromocriptine.

Bradycardia-Inducing Drugs (e.g., beta-blockers): Lanreotide Injection may decrease heart rate. Dosage adjustment of the coadministered drug may be necessary.

Drug Metabolism Interactions: Avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). Drugs metabolized by the liver may be metabolized more slowly during Lanreotide Injection treatment; dose reductions of the concomitantly administered medications should be considered.

Use in Specific Populations

Pregnancy: The risk of major birth defects and miscarriage is unknown.

Lactation: Advise women not to breastfeed during treatment with Lanreotide Injection and for 6 months following the last dose.

Females and Males of Reproductive Potential: Lanreotide Injection may reduce fertility in females of reproductive potential.

Geriatric Use: Dose selection for an elderly patient should be cautious.

You may report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.

Please see the full Prescribing Information for additional Important Safety Information.

Important Safety Information
Please Read Before Administration
Indications

Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Important Safety Information

Contraindications: Hypersensitivity to lanreotide.

Warnings and Precautions

Cholelithiasis and Complications of Cholelithiasis: Monitor patients periodically. Discontinue if complications of Cholelithiasis are suspected. Gallstones may occur; consider periodic monitoring.

Hyperglycemia and Hypoglycemia: Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly.

Most Common Adverse Reactions (>10%) include abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, hyperglycemia, hypertension, and cholelithiasis.

Immunogenicity: There is potential for immunogenicity.

Drug Interactions

Insulin and Oral Hypoglycemic Drugs: Blood glucose levels should be monitored and antidiabetic treatment should be adjusted accordingly.

Cyclosporine: Lanreotide Injection may decrease the absorption of cyclosporine. Dosage adjustment of cyclosporine may be needed.

Bromocriptine: Lanreotide may increase the absorption of bromocriptine.

Bradycardia-Inducing Drugs (e.g., beta-blockers): Lanreotide Injection may decrease heart rate. Dosage adjustment of the coadministered drug may be necessary.

Drug Metabolism Interactions: Avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). Drugs metabolized by the liver may be metabolized more slowly during Lanreotide Injection treatment; dose reductions of the concomitantly administered medications should be considered.

Use in Specific Populations

Pregnancy: The risk of major birth defects and miscarriage is unknown.

Lactation: Advise women not to breastfeed during treatment with Lanreotide Injection and for 6 months following the last dose.

Females and Males of Reproductive Potential: Lanreotide Injection may reduce fertility in females of reproductive potential.

Geriatric Use: Dose selection for an elderly patient should be cautious.

You may report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.

Please see the full Prescribing Information for additional Important Safety Information.